Belgravia Capital International receives cash payment, appoints renowned Dermatologist as special advisor to ICP Organics, and provides updates on additional blockchain developments

TORONTO, 2018-01-10 13:00 CET (GLOBE NEWSWIRE) --
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) ("Belgravia
Capital", "Belgravia", or the "Company") is pleased to announced that the
second cash payment of USD $1.4 million, due from Cartesian Capital Group
controlled Intercontinental Potash Corp. (USA) has been received.  The Canadian
equivalent amount received is $1.74 million. Current working capital, prior to
the completion of the current financing, announced on January 3, 2018, is CAD
$5.1 million. 

The Company is pleased to announce that Dr. Sam Hanna, a recognized Canadian
dermatologist has been appointed as Special Advisor to Belgravia's wholly owned
subsidiary, ICP Organics Corp. ("ICP Organics").  As announced on March 28,
2017, ICP Organics will focus on increasing the health impact and effects for
consumers of medicinal cannabis in its various formats. Dr. Hanna, is a
practicing dermatologist.  Cannabidiol ("CBD") is a cannabinoid found
throughout the seeds, stalk and flowers of cannabis plants including hemp. Hemp
and hemp derived CBD products are among the fastest growing segments in the
cannabis industry. According to a report by market intelligence firm Hemp
Business Journal the CBD market may grow to $2.1 billion by 2020.  According to
a published study in the Journal of Clinical Investigation, published September
2014, there is sufficient scientific data to strongly encourage future study in
clinical trials to determine whether either systemic or topical application of
CBD and/or appropriate modulation of the related signalling pathways deserves
full clinical exploration as a potent novel class of anti-acne agents.
According to the Journal of the American Academy of Dermatology, as published
in an article July 2017, Cannabinoids may have anti-inflammatory properties
useful for the treatment of both allergic contact dermatitis and atopic
dermatitis. 

Mr. Mehdi Azodi, the President and Chief Executive Officer of Belgravia stated:
"We are very pleased to have Dr. Hanna join the advisory panel of ICP Organics,
as we seek to expand our horizons in the legal medicinal cannabis business. In
addition, we are continuing to develop the specifications for our blockchain
concepts with respect to distributed databases as a service to retail
consumers, and as a value-added technology for the medical cannabis industry.
In addition to the developments, previously announced, we are investigating an
additional blockchain concept, which may have the potential to provide a
dramatic and significantly disruptive solution for certain aspects of customer
generation and retention for licensed producers, and other distributors of
legal cannabis products, around the world." 

Mr. Azodi continued: "As previously announced the company has investments of
approximately $675,000 in a developing portfolio of strategic research and
development investments in companies which will provide value-added services to
Belgravia in terms of profitable ideas and relationships in the legal medicinal
cannabis industry and the blockchain sector.  Based on current working capital,
and the shortly anticipated closing of the current financing, we expect to
expand this strategic investment portfolio.  This will include taking an active
role in the management of the operations of these investee companies in certain
cases." 

About Belgravia Capital
Belgravia Capital International is focused on the provision of clearly
value-added services to the international legal Cannabis industry.  This
includes the production of specialized organic fertilizers for Cannabis Sativa
plants, and the organization and development of blockchain technology software
for seed-to-sale tracking and quality attestation of intermediate and consumer
products. The wholly owned subsidiary of Belgravia, ICP Organics, is a research
and development company incorporating agronomic and health perspectives in the
Cannabis space. Belgravia is also developing a royalty-streaming subsidiary. 

Belgravia Capital intends to establish joint research and development
partnerships with Licensed Producers operating under ACMPR regulations in
Canada and in other jurisdictions where medicinal cannabis is fully legal.
Belgravia Capital may invest in various private and public companies in
diversified sectors on an opportunistic basis. For more information, please
visit www.belgraviacapital.ca. 

Forward-Looking Statements
Certain information set forth in this news release may contain forward-looking
statements that involve substantial known and unknown risks and uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. Forward-looking statements include statements that use
forward-looking terminology such as "may", "will", "expect", "anticipate",
"believe", "continue", "potential" or the negative thereof or other variations
thereof or comparable terminology. Such forward-looking statements include,
without limitation, statements regarding planned investment activities &
related returns, trends in the markets for fertilizers and medicinal or
recreational use of cannabis, the timing or assurance of the legalization of
recreational cannabis, the timing for completion of research and development
activities, the potential value of royalties from water and other resources,
and other statements that are not historical facts. These forward-looking
statements are subject to numerous risks and uncertainties, certain of which
are beyond the control of the Company, including, but not limited to, changes
in market trends, the completion, results and timing of research undertaken by
the Company, risks associated with resource assets, the impact of general
economic conditions, commodity prices, industry conditions, dependence upon
regulatory, environmental, and governmental approvals, the uncertainty of
obtaining additional financing, and risks associated with cannabis use for
medicinal or recreational purposes. Readers are cautioned that the assumptions
used in the preparation of such information, although considered reasonable at
the time of preparation, may prove to be imprecise and, as such, undue reliance
should not be placed on forward-looking statements. 

For More Information, Please Contact:
Mehdi Azodi, President & CEO
Belgravia Capital
[phone]
[e-mail]